78. Adjuvants for influenza vaccines
Session: Symposium: Innovations in Influenza Vaccines: Strategic Advances in Improving Immunogenicity
Thursday, October 20, 2011: 3:25 PM
Room: 253ABC

Martin Friede, PhD, World Health Organization, Geneva, Switzerland

Dr Martin Friede currently leads the technology transfer team within the department on innovation, information, evidence and research (IER) at the World Health Organization in Geneva, Switzerland. Prior to taking this position he was the WHO focal point for matters related to the development and use of adjuvants, as well as technologies to facilitate vaccine delivery such as needle-free systems, and vaccine stabilization methods. Dr Friede created the WHO's Global Adjuvant Development Initiative to facilitate supply of adjuvants and know-how on vaccine formulation to public sector vaccine developers. Prior to joining WHO Dr Friede held several positions in the vaccine industry. He received his PhD in biochemistry from the University of Cape Town in South Africa.

Findings in the abstracts are embargoed until 12:01 a.m. EST Thursday, Oct. 20 with the exception of research findings presented at IDSA press conferences.